ArticleActa neuropathologica communications2023
MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value.
Article in Acta neuropathologica communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Predictive value of EGFR amplification and EGFRvIII mutation in EGFR-targeted therapy for recurrent glioblastoma: a systematic review.CNS oncology · 2026Pooled it
- A systematic review of high impact CpG sites and regions for MGMT methylation in glioblastoma [A systematic review of MGMT methylation in GBM].BMC neurology · 2024Pooled it
- Recurrent mechanisms of biallelic epigenetic inactivation reveal new putative tumour suppressor genes in prostate cancer.Nature communications · 2026Article
- A scoping review of DNA methylation biomarkers for non-invasive detection of colorectal cancer at the CpG site level.Clinical epigenetics · 2026Article
- Construction and external validation of a prognostic model for high-grade glioma based on IDH1 mutation status: implications for concurrent chemoradiotherapy efficacy.American journal of cancer research · 2026Article
- Magnetic susceptibility properties of tumor-associated cells imaged by MRI reveal glioblastoma infiltration in the edema region.Communications medicine · 2025Article
- A MGMT Enhancer Variant is Associated with Glioma Susceptibility and Progression.Cellular and molecular neurobiology · 2025Article
- Beyond the Promoter: Total MGMT Gene Methylation Modulates Response to DNA-Alkylating Agents in Glioma.Molecular cancer therapeutics · 2025Article
- Radiomics and AI-Based Prediction of MGMT Methylation Status in Glioblastoma Using Multiparametric MRI: A Hybrid Feature Weighting Approach.Diagnostics (Basel, Switzerland) · 2025Article
- IDH mutation and MGMT methylation status in glioblastoma and other gliomas patients: a Russian retrospective cohort study.Journal of the Egyptian National Cancer Institute · 2025Article
- Validating a clinically based MS-MLPA threshold through comparison with Sanger sequencing in glioblastoma patients.Clinical epigenetics · 2025Article
- Going viral: targeting glioblastoma using oncolytic viruses.Immunotherapy advances · 2025Review
- Temozolomide use in elderly patients with MGMT promoter unmethylated glioblastoma: Is it finally time to dismount a dead horse?Neuro-oncology · 2024Article
- Clinical and molecular features of patients with IDH1 wild-type primary glioblastoma presenting unexpected short-term survival after gross total resection.Journal of neuro-oncology · 2024Article
- MGMT ProFWise: Unlocking a New Application for Combined Feature Selection and the Rank-Based Weighting Method to Link MGMT Methylation Status to Serum Protein Expression in Patients with Glioblastoma.International journal of molecular sciences · 2024Article
- Detection of O6-methylguanine-DNA methyltransferase gene methylation status in IDH-wild type glioblastomas using methylation-specific qPCR: a first report from Morocco.The Pan African medical journal · 2024Article
- Breaking boundaries: A rare case of glioblastoma with uncommon extraneural metastases: A case report and literature review.Brain & spine · 2024Article
- Research progress on S-palmitoylation modification mediated by the ZDHHC family in glioblastoma.Frontiers in cell and developmental biology · 2024Review
- Advancements in the clinical application of gene methylation for early cancer detection.Frontiers in epigenetics and epigenomics · 2024Review
- Association ofCancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment with the alkylating agent temozolomide is known to be prognostically beneficial in a subset of glioblastoma patients. Response to such chemotherapeutic treatment and the prognostic benefit have been linked to the methylation status of O
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.